PREPARATION AND EVALUATION OF CIPROFLOXACIN IMPLANTS USING BOVINE HYDROXYAPATITE-CHITOSAN COMPOSITE AND GLUTARALDEHYDE FOR OSTEOMYELITIS

  • Karina Citra Rani Post Graduated student of Airlangga Univeristy, Dharmawangsa Dalam, Surabaya 60286, East Java, Indonesia
  • Riesta Primaharinastiti Airlangga University
  • Esti Hendradi Airlangga University

Abstract

Objective: The objective of this study was to develop and evaluate a controlled release implant of ciprofloxacin using Bovine Hydroxyapatite-Chitosan composite and glutaraldehyde as cross-link agent.

Methods: Ciprofloxacin implants were prepared using Bovine Hydroxyapatite-Chitosan composite composition 70:30. This composite was further developed using three different concentrations of glutaraldehyde (0.5%, 0.75%, and 1,0%). Implants were formed into pellets with 4.0 mm diameters and weighed 100.0 mg using compression method. Further, the prepared ciprofloxacin implants were characterized for porosity, density, water absorption capacity, swelling ratio, degradation test, compressive strength, compatibility studies (FT-IR), morphology (SEM), X-ray diffraction study, assay, and in vitro drug release.

Results: The addition of glutaraldehyde as cross-link agent in ciprofloxacin implants showed controlled release profile of ciprofloxacin over a time period 30 d. This is caused by glutaraldehyde formed compact structure, so the porosity, water absorption capacity, and swelling ratio of the implants decreased. Scanning Electron Microscope photomicrograph revealed low porosity of the implants after cross-linking with glutaraldehyde. The FTIR study confirmed the formation of covalent imine bonds between Chitosan and glutaraldehyde. However, the addition of glutaraldehyde as a cross-link agent caused a decrease in the mechanical strength of the implants. Increased concentration of glutaraldehyde reduced the cristalinity of BHA and Chitosan, which were confirmed by XRD studies. In consequence, the mechanical strength of the implants decreases.

Conclusion: The results obtained from this study indicated that glutaraldehyde has the potential effect to retard ciprofloxacin release from Bovine Hydroxyapatite-Chitosan-ciprofloxacin implants for 30 d in the treatment of osteomyelitis.

 

Keywords: Ciprofloxacin, Bovine Hydroxyapatite, Chitosan, Glutaraldehyde, Cross-link, Implants, Osteomyelitis

Downloads

Download data is not yet available.

References

1. Porter JR, Ruckh TT, Popat KC. Bone tissue engineering: a review in bone biomimetics and drug delivery strategies. Biotechnol Prog 2009;25:1539-53.
2. Strobel C, Bormann N, Romacker A, Schmidmaier G, Wildemann B. Sequential release kinetics of two (gentamicin and BMP-2) or three (gentamicin, IGF-1 and BMP-2) substances from a one component polymeric coating on implants. J Controlled Release 2011;156:37-45.
3. Mourino V, Boccaccini AR. Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffolds. J R Soc Interface 2010;7:209-27.
4. Gogia JS, Meehan JP, Cesare PE, Jamali AA. Local antibiotic therapy in osteomyelitis. Seminars in Plastic Surgery 2009;23:100-7.
5. Aviv M, Berdicevsky I, Zilberman M. Gentamicin-loaded bioresorbable films for prevention of bacterial infections associated with orthopedic implants. J Biomed Mater Res A 2007;83:10-8.
6. Li B, Brown KV, Wenke JC, Guelcher SA. Sustained release of vancomycin from polyurethane scaffolds inhibits infection of bone wounds in a rat femoral segmental defect model. J Controlled Release 2010;145:221-30.
7. Dubnika A, Loca D, Cimdina LB. Functionalized hydroxyapatite scaffolds coated with sodium alginate and chitosan for controlled drug delivery. Proc Est Acad Sci 2012;61:193-9.
8. Iqbal MM, Gupta S, Sagar S, Ibrahim M. Design and evaluation of subcutaneous implantable drug delivery system of tramadol using natural biodegradable polymer. Ann Phytomed 2012;1:30-8.
9. Lambert HP, O’Grady FW. Quinolones. In: Lambert HP, Grady O. editors. Antibiotic and Chemotherapy. 6th ed. Edinburgh: Churchill Livingstone; 1992. p. 245-62.
10. Armstrong EP, Elsberry VA. Bone and joint infections. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. editors. Pharmacoteraphy. A Patophysiologic Approach. 3rd ed. Stamford: Appleton and Lange; 1997. p. 2221-35.
11. Jin HH, Kim DH, Kim TW, Shin KK, Jung JS, Park HC, et al. In vivo evaluation of porous hydroxyapatite/chitosan-alginate composite scaffold for bone tissue engineering. Int J Biol Macromol 2012;51:1079-85.
12. Usha KM, Nandeesh BN. Physiology of bone formation, remodeling, and metabolism. In: Radionuclide and Hybrid Bone Imaging. Berlin: Springer Berlin Heidelberg; 2012. p. 29-57.
13. Teng SH, Lee EJ, Wang P, Jun SH, Han CM, Kim HE. Functionally gradient chitosan/hydroxyapatite composite scaffolds for controlled drug release. J Biomed Mater Res Part B 2009;90:275-82.
14. Monteiro OA, Airoldi JC. Some studies of crosslinking chitosan-glutaraldehyde interaction in a homogeneous system. Int J Biol Macromol 1999;7:209-27.
15. Ostrowska J, Pierog M, Gierszweka M. State of water in non-crosslinked and crosslinked hydrogel chitosan membranes. Prog Chem Appl Chitin Its Deriv 2011;16:147-56.
16. Lei L, Li L, Zang L. Structure and performance of nano-hydroxyapatite filled biodegradable poly(1,2-propanediol-sebacate)-citrate) elastomer. Polym Degrad Stab 2009;94:1494-502.
17. Campos MG, Rawls HR, Innocentini-Mei LH, Satsangi N. In vitro gentamicin sustained and controlled release from chitosan cross-linked films. J Mater Sci: Mater Med 2009;20:537-42.
18. Liuyun J, Yubao L, Chengdong X. Preparation and biological properties of a novel composite scaffold of nano-hydroxyapatite/chitosan/carboxymethyl cellulose for bone tissue engineering. J Biomed Sci 2009;16:1-10.
19. Ashish P, Derle Deelip V. Development of cost effective biodegradable implants of ciprofloxacin hydrochloride in the treatment of osteomyelitis. Asian J Pharm 2012;2:19-37.
20. Budiatin SA, Zainuddin M, Khotib J. Biocompatible composite as gentamicin delivery system for osteomyelitis and bone regeneration. Int J Pharm Sci 2014;6:1-3.
21. Yang B, Li XY, Shi S, Kong X, Guo G, Huang M. Preparation and characterization of a novel chitosan scaffold. Carbohydr Polym 2010;80:860-5.
22. Teng SH, Lee EJ, Wang P, Jun SH, Han CM, Kim HE. Chitosan/nanohydroxyapatite composite membranes via dynamic filtration for guided bone regeneration. J Biomed Mater Res Part B 2008;88:569-79.
23. Han WW, Misra RD. Biomimetic chitosan-nanohydroxyapatite composite scaffolds for bone tissue engineering. Acta Biomater 2009;5:1182-97.
24. Ashish YP, Derle DV, Gandhi PP, Nade VN, Patel JS. In vitro and in vivo characterization of a novel biocompatible implants system for the sustained delivery of ciprofloxacin hydrochloride. J Pharm Res 2010;3:2122-6.
25. Stallmann HP, Faber C, Bronckers AL, Amerogen AV, Wuisman PI. In vitro gentamicin release from commercially available calcium phosphate bone substitute influence of carrier type on the duration of the release profile. BMC Musculoskeletal Disord 2006;7:1-8.
26. Berger J, Reist M, Maayer JM, Felt O, Peppas NA, Gunny R. Structure and interactions in covalently and ionically crosslinked chitosan hydrogels for biomedical applications. Eur J Pharm Biopharm 2004;57:19-34.
27. Mirzaei BE, Ramzani SA, Shaifee M, Dannaei M. Studies on glutaraldehyde crosslinked chitosan hydrogel properties for drug delivery system. Int J Polym Mater Polym 2015;62:605-11.
28. Goncalves VL, Laranjeira MC, Favere VT. Effect of crosslinking agents on chitosan microspheres in controlled release of diclofenac sodium. Polim Cienc Tecnol 2005;15:6-12.
29. Prabaharan M, Perez MA, Saja JA, Mano JF. Preparation and characterization of poly(L-lactic acid)-chitosan hybrid scaffolds with drug release capability. J Biomed Mater Res Part B 2006;88:427-34.
30. Silva RM, Silva GA, Coutinho OP, Mano JF, Reis RL. Preparation and characterization in simulated body conditions of glutaraldehyde crosslinked chitosan membranes. J. Mater Sci Mater Med 2004;1105-12.
31. Sailakshmi G, Mitra T, Chatterjee S, Gnanamani A. Chemistry behind the elastic nature of the biomaterial prepared using oxidized form of glutaraldehyde. Int J Life Sci Med Res 2013;4:64-75.
32. Makinen TJ, Veiranto M, Lankinen P, Moritz N, Jalava J, Tormala P, et al. In vitro and in vivo release of ciprofloxacin from osteoconductive bone defect filler. J Antimicrob Chemother 2005;56:1063-8.
33. Mont MA, Mathur SK, Carmelita G, Frondoza D, Hungerford DS. The effects of ciprofloxacin on human chondrocytes in cell culture. Infection 1996;24:151-5.
34. Li B, Shan CL, Zhou Q, Fang Y, Wang YL, Xu F, et al. Synthesis, characterization, and antibacterial activity of cross-linked chitosan-glutaraldehyde. Mar Drugs 2013;11:1534-52.
35. Monteiro OA, Airoldi JC. Some studies of crosslinking chitosan-glutaraldehyde interaction in a homogeneous system. Int J Biol Macromol 1999;26:119-28.
Statistics
424 Views | 3578 Downloads
How to Cite
Rani, K. C., R. Primaharinastiti, and E. Hendradi. “PREPARATION AND EVALUATION OF CIPROFLOXACIN IMPLANTS USING BOVINE HYDROXYAPATITE-CHITOSAN COMPOSITE AND GLUTARALDEHYDE FOR OSTEOMYELITIS”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 8, no. 1, Nov. 2015, pp. 45-51, https://innovareacademics.in/journals/index.php/ijpps/article/view/8484.
Section
Original Article(s)